Skip to content

The Clinical Study of acupoint application with iontophoresis in the treatment of Child Asthma

The Clinical Study of acupoint application with iontophoresis in the treatment of Child Asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009902
Enrollment
Unknown
Registered
2016-11-17
Start date
2016-12-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child Asthma

Interventions

acupoint application with iontophoresis treatment group:acupoint application with iontophoresis treatment
acupoint application treatment group:acupoint application treatment
Un-acupoint application treatment group:Chinese medicine with western basis treatment

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medcine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 5-14 years old children with asthma in remission period with Chinese medicine diagnosis 'shen qi deficiency' zhen, 'lung qi deficiency' and 'spleen qi deficiency' zhen; 2. The history of treating time of acupoint application was less than 3 years; 3. Had repeated attack of asthma history and had complete outpatient records; 4. Voluntary takes part in the trial, and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who not meet the Western medicine diagnosis and the Traditional Chinese medicine diagnosis; 2. Patients with severe-to-critical acute exacerbation of asthma; 3. Patients who haven't attacked asthma for one year before taking acupoint application; 4. With other severe cardiac,lung and immunological diseases; 5. Allergy to medical plasters or any component of drugs in the present study; 6. Patients who are taking part in other acupoint application study; 7. Patients with COPD, bronchiectasis, tracheobronchial foreign body, pulmonary tuberculosis disease;patients with severe primary cardiac, liver, lung, kidney, Endocrine and metabolic systemnervous system and hemopoietic system diseases; 8. Patients with skin lesions.

Design outcomes

Primary

MeasureTime frame
attack frequency;The degree of attack;

Secondary

MeasureTime frame
lung function;ECP;EOS;

Countries

China

Contacts

Public ContactZhao Jun

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medcine

annezhao@sina.com+86 13671956320

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026